Bayer Hlthcare Drug Patent Portfolio
Bayer Hlthcare owns 27 orange book drugs protected by 88 US patents with Climara Pro having the least patent protection, holding only 1 patent. And Vitrakvi with maximum patent protection, holding 15 patents. Given below is the list of Bayer Hlthcare's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11337967 | Methods of treatment | 16 May, 2037 | Active |
| US11974998 | Methods of treatment | 16 May, 2037 | Active |
| US10799505 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 15 Aug, 2036 | Active |
| US10172861 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 16 Nov, 2035 | Active |
| US10285993 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 16 Nov, 2035 | Active |
| US10813936 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 16 Nov, 2035 | Active |
| US9782414 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 16 Nov, 2035 | Active |
| USRE49826 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient | 29 Jul, 2035 | Active |
| US10662188 | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate | 18 Feb, 2034 | Active |
| US11203593 | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate | 18 Feb, 2034 | Active |
| US9957232 | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate | 09 Jul, 2032 | Active |
| US8906890 | Very low-dosed solid oral dosage forms for HRT | 22 Oct, 2031 | Active |
| US9458107 | Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate | 08 Apr, 2031 | Active |
| US10987244 | Inserter | 01 Apr, 2031 | Active |
| US9668912 | Inserter | 01 Apr, 2031 | Active |
| US8637553 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | 16 Feb, 2031 | Active |
| US11617751 | Pharmaceutical composition containing a tetrahydrofolic acid | 17 Jul, 2030 | Active |
| US8680124 | Treatment of cancers with acquired resistance to kit inhibitors | 02 Jun, 2030 | Active |
| US8617597 | Pharmaceutical composition containing a tetrahydrofolic acid | 08 Feb, 2030 | Active |
| US8513263 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | 23 Dec, 2029 | Active |
| US10005783 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | 21 Oct, 2029 | Active |
| US10047097 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | 21 Oct, 2029 | Active |
| US10774085 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | 21 Oct, 2029 | Active |
| US8865698 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | 21 Oct, 2029 | Active |
| US9127013 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | 21 Oct, 2029 | Active |
| US9447104 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | 21 Oct, 2029 | Active |
| US9676783 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | 21 Oct, 2029 | Active |
| US10561524 | Inserter | 16 Sep, 2029 | Active |
| US9615965 | Inserter | 16 Sep, 2029 | Active |
| US11850182 | Inserter | 14 Sep, 2029 | Active |
| US8436180 | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | 12 Apr, 2029 | Active |
| US8613950 | Pharmaceutical forms with improved pharmacokinetic properties | 23 Dec, 2028 | Active |
| US9737488 | Pharmaceutical composition for the treatment of cancer | 10 Sep, 2028 | Active |
| US8071073 | Compositions comprising azelastine and methods of use thereof | 04 Jun, 2028 | Active |
| US8153616 | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same | 30 Jan, 2028 | Active |
| US8877933 | Thermodynamically stable form of a tosylate salt | 24 Dec, 2027 | Active |
| US8273876 | Medicaments containing vardenafil hydrochloride trihydrate | 23 Jul, 2027 | Active |
| US8791127 | Mucosal bioadhesive slow release carrier for delivering active principles | 23 Mar, 2027 | Active |
| US11628088 | Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection | 07 Feb, 2027 | Active |
| US7173037 | Carbamate-substituted pyrazolopyridines | 04 Dec, 2026 | Active |
| US8071577 | Multi-phase contraceptive preparation based on a natural estrogen | 13 May, 2026 | Active |
| US8518919 | Compositions comprising azelastine and methods of use thereof | 22 Nov, 2025 | Active |
| US9919050 | Compositions comprising azelastine | 22 Nov, 2025 | Active |
| US7252839 | Delivery system and a manufacturing process of a delivery system | 13 Nov, 2023 | Expired |
| US8841446 | Medicaments containing vardenafil hydrochloride trihydrate | 03 Jul, 2023 | Expired |
| US8618141 | Aryl ureas with angiogenesis inhibiting activity | 11 Feb, 2023 | Expired |
| US7709022 | Sustained-release preparations of quinolone antibiotics and method for preparation thereof | 23 Dec, 2021 | Expired |
| US8187632 | Sustained-release preparations of quinolone antibiotics | 23 Dec, 2021 | Expired |
| US6958326 | Cyclodextrin-drospirenone inclusion complexes | 20 Dec, 2021 | Expired |
| US7163931 | Compositions of estrogen-cyclodextrin complexes | 20 Dec, 2021 | Expired |
| US6039931 | Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production | 13 Nov, 2021 | Expired |
| US5980864 | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them | 09 Nov, 2021 | Expired |
| US7709022 | Sustained-release preparations of quinolone antibiotics and method for preparation thereof | 23 Jun, 2021 | Expired |
| US8187632 | Sustained-release preparations of quinolone antibiotics | 23 Jun, 2021 | Expired |
| US6787531 | Pharmaceutical composition for use as a contraceptive | 31 Aug, 2020 | Expired |
| US6548079 | Moxifloxacin formulation containing common salt | 25 Jul, 2020 | Expired |
| US6441168 | Stable crystalline salts of 5-methyltetrahydrofolic acid | 17 Apr, 2020 | Expired |
| US7235576 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | 12 Jan, 2020 | Expired |
| US7351834 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | 12 Jan, 2020 | Expired |
| US7897623 | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors | 12 Jan, 2020 | Expired |
| US8124630 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | 12 Jan, 2020 | Expired |
| US8841330 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | 12 Jan, 2020 | Expired |
| US6635234 | Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning | 03 Jan, 2020 | Expired |
| US6610327 | Pharmaceutical moxifloxacin preparation | 29 Oct, 2019 | Expired |
| US6743798 | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings | 16 Jul, 2019 | Expired |
| US6362178 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | 31 Oct, 2018 | Expired |
| US7696206 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | 31 Oct, 2018 | Expired |
| US6987101 | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder | 22 Dec, 2017 | Expired |
| US5891868 | Methods for treating postmenopausal women using ultra-low doses of estrogen | 21 Nov, 2017 | Expired |
| US6692763 | Methods for treating postmenopausal women using ultra-low doses of estrogen | 21 Nov, 2017 | Expired |
| US6933395 | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY | 11 Aug, 2017 | Expired |
| US5849752 | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification | 05 Dec, 2016 | Expired |
| US6133251 | Combination compound for contraception based on natural estrogen | 25 Oct, 2016 | Expired |
| US6884793 | Combination preparation for contraception based on natural estrogens | 25 Oct, 2016 | Expired |
| US5785053 | Inserter for the positioning of an intrauterine device | 05 Dec, 2015 | Expired |
| US5798092 | Derivatized DTPA complexes pharmaceutical agents containing these compounds, their use, and processes for their production | 25 Aug, 2015 | Expired |
| US5798338 | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol | 10 Jul, 2015 | Expired |
| US5695784 | Flavor-masked pharmaceutical compositions | 09 Jun, 2015 | Expired |
| US5695784 | Flavor-masked pharmaceutical compositions | 09 Dec, 2014 | Expired |
| US5676968 | Transdermal therapeutic systems with crystallization inhibitors | 14 Oct, 2014 | Expired |
| USRE37564 | Composition for contraception | 30 Jun, 2014 | Expired |
| USRE37838 | Composition for contraception | 30 Jun, 2014 | Expired |
| USRE38253 | Composition for contraception | 30 Jun, 2014 | Expired |
| USRE43916 | Composition for contraception | 30 Jun, 2014 | Expired |
| US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives | 04 Mar, 2014 | Expired |
| US5569652 | Dihydrospirorenone as an antiandrogen | 29 Oct, 2013 | Expired |
| US6136347 | Flavor-masked pharmaceutical compositions | 06 Jul, 2013 | Expired |
| US6136347 | Flavor-masked pharmaceutical compositions | 06 Jan, 2013 | Expired |
Latest Legal Activities on Bayer Hlthcare's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bayer Hlthcare.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 01 Jul, 2024 | US8187632 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Apr, 2024 | US10813936 |
|
Expire Patent
Critical
| 01 Apr, 2024 | US8124630 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 27 Mar, 2024 | US10799505 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Mar, 2024 | US9458107 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Mar, 2024 | US8273876 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Mar, 2024 | US9447104 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Feb, 2024 | US10774085 |
|
Maintenance Fee Reminder Mailed
Critical
| 15 Jan, 2024 | US8187632 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 26 Dec, 2023 | US11850182 |
| Patent eGrant Notification | 26 Dec, 2023 | US11850182 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 26 Dec, 2023 | US11850182 |
| Patent eGrant Notification | 26 Dec, 2023 | US11850182 |
| Mail Patent eGrant Notification | 26 Dec, 2023 | US11850182 |
| Recordation of Patent eGrant | 26 Dec, 2023 | US11850182 |
Bayer Hlthcare's Drug Patent Litigations
Bayer Hlthcare's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 17, 2005, against patent number US8124630. The petitioner , challenged the validity of this patent, with Bernd Riedl et al as the respondent. Click below to track the latest information on how companies are challenging Bayer Hlthcare's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9957232 | November, 2015 |
Decision
(14 Feb, 2017)
| Alfons Grunenberg et al | |
| US8637553 | July, 2016 |
Terminated-Denied
(08 Feb, 2017)
| Bayer HealthCare LLC | Fustibal LLC |
| US8071073 | May, 2014 |
Terminated-Denied
(29 Jul, 2014)
| Meda Pharmaceuticals Inc. | Impax Laboratories, Inc. |
| US8187632 | June, 2010 |
Decision
(08 Nov, 2011)
| Venkata-Rangarao Kanikanti et al | |
| US8124630 | June, 2005 |
Decision
(27 Dec, 2005)
| Bernd Riedl et al | |
Bayer Hlthcare Drug Patents' Oppositions Filed in EPO
Bayer Hlthcare drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 03, 2008, by N.V. Organon. This opposition was filed on patent number EP03797325A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP10183693A | Jul, 2017 | Accord Healthcare Ltd | Opposition rejected |
| EP10183693A | Jul, 2017 | Teva Pharmaceutical Industries Ltd | Opposition rejected |
| EP10183693A | Jul, 2017 | Zentiva k.s. | Opposition rejected |
| EP03707846A | Apr, 2014 | Accord Healthcare Ltd | Revoked |
| EP03707846A | Apr, 2014 | Hetero Drugs Ltd. | Revoked |
| EP07818583A | Mar, 2014 | Fresenius Kabi Deutschland GmbH | Opposition rejected |
| EP09736608A | Feb, 2014 | Actavis Group PTC ehf | Patent maintained as amended |
| EP09736244A | Sep, 2013 | Actavis Group PTC EHF | Patent maintained as amended |
| EP05797740A | Mar, 2013 | Biofer S.p.A. | Revoked |
| EP05797740A | Mar, 2013 | Fresenius Kabi Deutschland GmbH | Revoked |
| EP06706994A | Jan, 2013 | Generics [UK] Limited | Opposition rejected |
| EP06706994A | Jan, 2013 | Accord Healthcare Ltd | Opposition rejected |
| EP03763695A | Sep, 2012 | Accord Healthcare Ltd | Revoked |
| EP03763695A | Sep, 2012 | Zentiva k.s. | Revoked |
| EP06707141A | Jun, 2011 | Teva Pharmaceutical Industries Ltd. | Revoked |
| EP06707141A | Jun, 2011 | Altmann, Andreas | Revoked |
| EP05730867A | Apr, 2011 | Lupin Limited | Patent maintained as amended |
| EP05730867A | Apr, 2011 | Laboratorios Léon Farma, S.A. | Patent maintained as amended |
| EP05022324A | Nov, 2009 | Sandoz International GmbH | Revoked |
| EP03797325A | Dec, 2008 | N.V. Organon | Patent maintained as amended |
Bayer Hlthcare's Family Patents
Bayer Hlthcare Drug List
Given below is the complete list of Bayer Hlthcare's drugs and the patents protecting them.
1. Adempas
Adempas is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10662188 | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate |
18 Feb, 2034
(8 years from now)
| Active |
| US11203593 | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
18 Feb, 2034
(8 years from now)
| Active |
| US7173037 | Carbamate-substituted pyrazolopyridines |
04 Dec, 2026
(1 year, 6 months from now)
| Active |
| US6743798 | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
16 Jul, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adempas's drug page
2. Angeliq
Angeliq is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8906890 | Very low-dosed solid oral dosage forms for HRT |
22 Oct, 2031
(6 years from now)
| Active |
| US6933395 | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY |
11 Aug, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Angeliq's drug page
3. Astepro Allergy
Astepro Allergy is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8071073 | Compositions comprising azelastine and methods of use thereof |
04 Jun, 2028
(3 years from now)
| Active |
| US8518919 | Compositions comprising azelastine and methods of use thereof |
22 Nov, 2025
(6 months from now)
| Active |
| US9919050 | Compositions comprising azelastine |
22 Nov, 2025
(6 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Astepro Allergy's drug page
4. Avelox
Avelox is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6610327 | Pharmaceutical moxifloxacin preparation |
29 Oct, 2019
(5 years ago)
| Expired |
| US5849752 | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification |
05 Dec, 2016
(8 years ago)
| Expired |
| US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
04 Mar, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avelox's drug page
5. Avelox In Sodium Chloride 0.8% In Plastic Container
Avelox In Sodium Chloride 0.8% In Plastic Container is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6548079 | Moxifloxacin formulation containing common salt |
25 Jul, 2020
(4 years ago)
| Expired |
| US5849752 | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification |
05 Dec, 2016
(8 years ago)
| Expired |
| US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
04 Mar, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avelox In Sodium Chloride 0.8% In Plastic Container's drug page
Explore Our Curated Drug Screens
6. Beyaz
Beyaz is protected by 10 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11617751 | Pharmaceutical composition containing a tetrahydrofolic acid |
17 Jul, 2030
(5 years from now)
| Active |
| US8617597 | Pharmaceutical composition containing a tetrahydrofolic acid |
08 Feb, 2030
(4 years from now)
| Active |
| US7163931 | Compositions of estrogen-cyclodextrin complexes |
03 Mar, 2022
(3 years ago)
| Expired |
| US6958326 | Cyclodextrin-drospirenone inclusion complexes |
30 Dec, 2021
(3 years ago)
| Expired |
| US6441168 | Stable crystalline salts of 5-methyltetrahydrofolic acid |
17 Apr, 2020
(5 years ago)
| Expired |
| US5798338 | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
10 Jul, 2015
(9 years ago)
| Expired |
| USRE37564 | Composition for contraception |
30 Jun, 2014
(10 years ago)
| Expired |
| USRE37838 | Composition for contraception |
30 Jun, 2014
(10 years ago)
| Expired |
| USRE38253 | Composition for contraception |
30 Jun, 2014
(10 years ago)
| Expired |
| USRE43916 | Composition for contraception |
30 Jun, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Beyaz's drug page
7. Children's Astepro Allergy
Children's Astepro Allergy is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8071073 | Compositions comprising azelastine and methods of use thereof |
04 Jun, 2028
(3 years from now)
| Active |
| US8518919 | Compositions comprising azelastine and methods of use thereof |
22 Nov, 2025
(6 months from now)
| Active |
| US9919050 | Compositions comprising azelastine |
22 Nov, 2025
(6 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Children's Astepro Allergy's drug page
8. Cipro
Cipro is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5695784
(Pediatric)
| Flavor-masked pharmaceutical compositions |
09 Jun, 2015
(9 years ago)
| Expired |
| US5695784 | Flavor-masked pharmaceutical compositions |
09 Dec, 2014
(10 years ago)
| Expired |
| US6136347
(Pediatric)
| Flavor-masked pharmaceutical compositions |
06 Jul, 2013
(11 years ago)
| Expired |
| US6136347 | Flavor-masked pharmaceutical compositions |
06 Jan, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cipro's drug page
9. Cipro Xr
Cipro Xr is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7709022
(Pediatric)
| Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
23 Dec, 2021
(3 years ago)
| Expired |
| US8187632
(Pediatric)
| Sustained-release preparations of quinolone antibiotics |
23 Dec, 2021
(3 years ago)
| Expired |
| US7709022 | Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
23 Jun, 2021
(3 years ago)
| Expired |
| US8187632 | Sustained-release preparations of quinolone antibiotics |
23 Jun, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cipro Xr's drug page
10. Climara Pro
Climara Pro is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5676968 | Transdermal therapeutic systems with crystallization inhibitors |
14 Oct, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Climara Pro's drug page
11. Eovist
Eovist is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6039931 | Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production |
13 Nov, 2021
(3 years ago)
| Expired |
| US5798092 | Derivatized DTPA complexes pharmaceutical agents containing these compounds, their use, and processes for their production |
25 Aug, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eovist's drug page
12. Gadavist
Gadavist is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5980864 | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
09 Nov, 2021
(3 years ago)
| Expired |
| US5980864 | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
09 Nov, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gadavist's drug page
13. Kerendia
Kerendia is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE49826 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
29 Jul, 2035
(10 years from now)
| Active |
| US8436180 | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
12 Apr, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kerendia's drug page
14. Kyleena
Kyleena is protected by 7 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10987244 | Inserter |
01 Apr, 2031
(5 years from now)
| Active |
| US9668912 | Inserter |
01 Apr, 2031
(5 years from now)
| Active |
| US10561524 | Inserter |
16 Sep, 2029
(4 years from now)
| Active |
| US9615965 | Inserter |
16 Sep, 2029
(4 years from now)
| Active |
| US11850182 | Inserter |
14 Sep, 2029
(4 years from now)
| Active |
| US11628088 | Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection |
07 Feb, 2027
(1 year, 8 months from now)
| Active |
| US7252839 | Delivery system and a manufacturing process of a delivery system |
13 Nov, 2023
(1 year, 6 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kyleena's drug page
15. Levitra
Levitra is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8273876 | Medicaments containing vardenafil hydrochloride trihydrate |
23 Jul, 2027
(2 years from now)
| Active |
| US8841446 | Medicaments containing vardenafil hydrochloride trihydrate |
03 Jul, 2023
(1 year, 10 months ago)
| Expired |
| US6362178 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
31 Oct, 2018
(6 years ago)
| Expired |
| US7696206 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
31 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levitra's drug page
16. Menostar
Menostar is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5891868 | Methods for treating postmenopausal women using ultra-low doses of estrogen |
21 Nov, 2017
(7 years ago)
| Expired |
| US6692763 | Methods for treating postmenopausal women using ultra-low doses of estrogen |
21 Nov, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Menostar's drug page
17. Mirena
Mirena is protected by 6 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10987244 | Inserter |
01 Apr, 2031
(5 years from now)
| Active |
| US9668912 | Inserter |
01 Apr, 2031
(5 years from now)
| Active |
| US10561524 | Inserter |
16 Sep, 2029
(4 years from now)
| Active |
| US9615965 | Inserter |
16 Sep, 2029
(4 years from now)
| Active |
| US11850182 | Inserter |
14 Sep, 2029
(4 years from now)
| Active |
| US5785053 | Inserter for the positioning of an intrauterine device |
05 Dec, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mirena's drug page
18. Natazia
Natazia is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8153616 | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
30 Jan, 2028
(2 years from now)
| Active |
| US8071577 | Multi-phase contraceptive preparation based on a natural estrogen |
13 May, 2026
(11 months from now)
| Active |
| US6133251 | Combination compound for contraception based on natural estrogen |
25 Oct, 2016
(8 years ago)
| Expired |
| US6884793 | Combination preparation for contraception based on natural estrogens |
25 Oct, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Natazia's drug page
19. Nexavar
Nexavar is protected by 8 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9737488 | Pharmaceutical composition for the treatment of cancer |
10 Sep, 2028
(3 years from now)
| Active |
| US8877933 | Thermodynamically stable form of a tosylate salt |
24 Dec, 2027
(2 years from now)
| Active |
| US8618141 | Aryl ureas with angiogenesis inhibiting activity |
11 Feb, 2023
(2 years ago)
| Expired |
| US7235576 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
12 Jan, 2020
(5 years ago)
| Expired |
| US7351834 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
12 Jan, 2020
(5 years ago)
| Expired |
| US7897623 | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
12 Jan, 2020
(5 years ago)
| Expired |
| US8124630 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
12 Jan, 2020
(5 years ago)
| Expired |
| US8841330 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
12 Jan, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexavar's drug page
20. Safyral
Safyral is protected by 6 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11617751 | Pharmaceutical composition containing a tetrahydrofolic acid |
17 Jul, 2030
(5 years from now)
| Active |
| US8617597 | Pharmaceutical composition containing a tetrahydrofolic acid |
08 Feb, 2030
(4 years from now)
| Active |
| US7163931 | Compositions of estrogen-cyclodextrin complexes |
03 Mar, 2022
(3 years ago)
| Expired |
| US6958326 | Cyclodextrin-drospirenone inclusion complexes |
20 Dec, 2021
(3 years ago)
| Expired |
| US6441168 | Stable crystalline salts of 5-methyltetrahydrofolic acid |
17 Apr, 2020
(5 years ago)
| Expired |
| US5798338 | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
10 Jul, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Safyral's drug page
21. Skyla
Skyla is protected by 8 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10987244 | Inserter |
01 Apr, 2031
(5 years from now)
| Active |
| US9668912 | Inserter |
01 Apr, 2031
(5 years from now)
| Active |
| US10561524 | Inserter |
16 Sep, 2029
(4 years from now)
| Active |
| US9615965 | Inserter |
16 Sep, 2029
(4 years from now)
| Active |
| US11850182 | Inserter |
14 Sep, 2029
(4 years from now)
| Active |
| US11628088 | Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection |
07 Feb, 2027
(1 year, 8 months from now)
| Active |
| US7252839 | Delivery system and a manufacturing process of a delivery system |
13 Nov, 2023
(1 year, 6 months ago)
| Expired |
| US5785053 | Inserter for the positioning of an intrauterine device |
05 Dec, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Skyla's drug page
22. Staxyn
Staxyn is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8613950 | Pharmaceutical forms with improved pharmacokinetic properties |
23 Dec, 2028
(3 years from now)
| Active |
| US6362178 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
31 Oct, 2018
(6 years ago)
| Expired |
| US7696206 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
31 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Staxyn's drug page
23. Stivarga
Stivarga is protected by 5 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9957232 | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate |
09 Jul, 2032
(7 years from now)
| Active |
| US9458107 | Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate |
08 Apr, 2031
(5 years from now)
| Active |
| US8637553 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
16 Feb, 2031
(5 years from now)
| Active |
| US8680124 | Treatment of cancers with acquired resistance to kit inhibitors |
02 Jun, 2030
(5 years from now)
| Active |
| US7351834 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
12 Jan, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Stivarga's drug page
24. Vitrakvi
Vitrakvi is protected by 15 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11337967 | Methods of treatment |
16 May, 2037
(11 years from now)
| Active |
| US11974998 | Methods of treatment |
16 May, 2037
(11 years from now)
| Active |
| US10799505 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
15 Aug, 2036
(11 years from now)
| Active |
| US10172861 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
16 Nov, 2035
(10 years from now)
| Active |
| US10285993 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
16 Nov, 2035
(10 years from now)
| Active |
| US10813936 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
16 Nov, 2035
(10 years from now)
| Active |
| US9782414 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
16 Nov, 2035
(10 years from now)
| Active |
| US8513263 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
23 Dec, 2029
(4 years from now)
| Active |
| US10005783 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
21 Oct, 2029
(4 years from now)
| Active |
| US10047097 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
21 Oct, 2029
(4 years from now)
| Active |
| US10774085 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
21 Oct, 2029
(4 years from now)
| Active |
| US8865698 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
21 Oct, 2029
(4 years from now)
| Active |
| US9127013 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
21 Oct, 2029
(4 years from now)
| Active |
| US9447104 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
21 Oct, 2029
(4 years from now)
| Active |
| US9676783 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
21 Oct, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vitrakvi's drug page
25. Xofigo
Xofigo is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8791127 | Mucosal bioadhesive slow release carrier for delivering active principles |
23 Mar, 2027
(1 year, 10 months from now)
| Active |
| US6635234 | Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning |
03 Jan, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xofigo's drug page
26. Yasmin
Yasmin is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6787531 | Pharmaceutical composition for use as a contraceptive |
31 Aug, 2020
(4 years ago)
| Expired |
| US6933395 | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY |
11 Aug, 2017
(7 years ago)
| Expired |
| US5569652 | Dihydrospirorenone as an antiandrogen |
29 Oct, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yasmin's drug page
27. Yaz
Yaz is protected by 11 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6958326 | Cyclodextrin-drospirenone inclusion complexes |
20 Dec, 2021
(3 years ago)
| Expired |
| US7163931 | Compositions of estrogen-cyclodextrin complexes |
20 Dec, 2021
(3 years ago)
| Expired |
| US6787531 | Pharmaceutical composition for use as a contraceptive |
31 Aug, 2020
(4 years ago)
| Expired |
| US6987101 | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
22 Dec, 2017
(7 years ago)
| Expired |
| US6933395 | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY |
11 Aug, 2017
(7 years ago)
| Expired |
| US5798338 | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
10 Jul, 2015
(9 years ago)
| Expired |
| USRE37564 | Composition for contraception |
30 Jun, 2014
(10 years ago)
| Expired |
| USRE37838 | Composition for contraception |
30 Jun, 2014
(10 years ago)
| Expired |
| USRE38253 | Composition for contraception |
30 Jun, 2014
(10 years ago)
| Expired |
| USRE43916 | Composition for contraception |
30 Jun, 2014
(10 years ago)
| Expired |
| US5569652 | Dihydrospirorenone as an antiandrogen |
29 Oct, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yaz's drug page